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Prostate metabolism is unique, characterised by cholesterol accumulation and reduced respiration.
Are these related? We modulated cholesterol levels and despite changes in mitochondrial choles-
terol content, we saw no effects on lactate production or respiration. Instead, these features may
be related via sterol regulatory element-binding protein 2 (SREBP-2), the master transcriptional reg-
ulator of cholesterol synthesis. SREBP-2 diverts acetyl-CoA into cholesterol synthesis and may thus
reduce respiration. We examined LNCaP cells overexpressing the SREBP-2 regulator, Scap: although
having higher SREBP-2 activity, these cells displayed higher respiration. This striking observation
warrants further investigation. Given that SREBP-2 and Scap are regulated by factors driving pros-
tate growth, exploring this observation further could shed light on prostate carcinogenesis.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In developed countries, prostate cancer (PCa) is the most
common cancer in men and has the second highest rate of
cancer-related mortality [1]. With no cure for the advanced
(‘castration-resistant’) stages of PCa, there is an urgent need to
better understand the mechanisms driving this disease. There
has been recent interest in cancer metabolism, with metabolic
changes being considered a hallmark of cancer [2] and a target
for cancer therapy [3].
In this vein, there are two metabolic features unique to
prostate epithelial cells. Firstly, normal prostate cells have higher
cholesterol synthesis than the liver, and elevated cholesterol lev-
els compared to the surrounding tissue [4]. This cholesterol accu-
mulation increases further in the ageing prostate and PCa [4].Secondly, the prostate displays high glycolytic activity and re-
duced respiration [5,6]. Here, we consider whether these features
are related.
For instance, cholesterol is hydrophobic, allowing it to embed
within the cellular membrane and decrease membrane ﬂuidity
[7]. This can pose a physical barrier to prevent oxygen diffusion
[7,8], as well as reducing passive proton permeability in mitochon-
dria [9]. High mitochondrial membrane-cholesterol content may
also disrupt mitochondrial proteins (e.g., [10,11]), which can im-
pair respiration [12]. Normally, the mitochondrial membranes
are cholesterol-poor [13,14], but become enriched with cholesterol
in cancers, thus inﬂuencing cancer metabolism. One well-studied
example are hepatomas [9,15–17], whereby enriching non-cancer-
ous liver mitochondrial membranes with cholesterol produced the
impaired mitochondrial activity observed in hepatomas [18]. Con-
versely, depleting cholesterol from hepatoma mitochondria im-
proved respiration efﬁciency [19]. Beyond the hepatoma setting,
heart mitochondrial membrane cholesterol levels increase during
ischaemia, leading to reduced State 3 respiration [20]. Given that
these two features (high cholesterol, reduced respiration) are pres-
ent in the prostate, we hypothesised a similar relationship may oc-
cur in the prostate setting; a link that has not been examined
previously.
Another unexplored relationship is between respiration and
cholesterol synthesis. To generate cholesterol, an intermediate of
the citric acid cycle, citrate, is shuttled out of the mitochondria
to provide acetyl-CoA for cholesterol synthesis. Indeed, high citrate
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ﬂux out of the citric acid cycle could impair respiration whilst fuel-
ling cholesterol synthesis.
A key regulator of cholesterol synthesis is the sterol regulatory
element-binding protein 2 (SREBP-2). This cholesterogenic tran-
scription factor upregulates the protein involved in cholesterol
uptake, the low-density lipoprotein receptor (LDLR), and the
majority of the enzymes in cholesterol biosynthesis, including
the ﬂux-controlling enzyme HMG-CoA reductase (HMGCR)
[23,24]. In turn, SREBP-2 activity is regulated by cholesterol via
an elegant feedback mechanism [25]: when cholesterol levels
are low, SREBP-2 is escorted by Scap from the endoplasmic retic-
ulum (ER) to the Golgi, where SREBP-2 is cleaved. This generates
the mature transcription factor, which upregulates cholesterol
synthesis and uptake. As cholesterol levels rise, Scap is bound
by the retention protein, Insig, in the ER. This prevents the activa-
tion of SREBP-2. We and others have shown that the activation of
SREBP-2 is enhanced by growth-promoting factors, with Akt ki-
nase promoting ER-to-Golgi transport of SREBP-2 [26,27] and
androgens upregulating Scap expression [28,29]. Both of these
factors are important for the PCa setting [30,31], implicating
SREBP-2 in PCa development [31].
Overall, there is evidence supporting a relationship between
cholesterol accumulation and diminished respiration in the pros-
tate setting. Thus, we aim to test two hypotheses: ﬁrstly, that
increasing cellular cholesterol levels impairs respiration, and sec-
ondly, that increasing SREBP-2 activity also impairs respiration. To-
gether, this could contribute to the metabolic phenotype observed
in prostate cells.
2. Materials and methods
2.1. Materials
Foetal calf serum (FCS) was obtained from Bovogen (Vic, AU),
newborn calf serum (NCS), zeocin and penicillin/streptomycin
from Life Technologies (Vic, AU), and all other media components
from Sigma–Aldrich (NSW, AU). Lipoprotein-deﬁcient NCS
(NCLPDS) was prepared from NCS, as described previously [32].
Methyl-b-cyclodextrin, (2-hydroxypropyl)-b-cyclodextrin, oligo-
mycin, 2,4-dinitrophenol, rotenone, and antimycin A were ob-
tained from Sigma–Aldrich. Cholesterol was obtained from
Steraloids (USA) and cholesterol/methyl-b-cyclodextrin complexes
were prepared as described previously [33].
2.2. Cell culture
The PCa cell-line, LNCaP, was a gift from Dr. Pamela Russell
(Australian Prostate Cancer Research Center, AU), and maintained
in Medium A (RPMI 1640, supplemented with 10% (v/v)
FCS, 100 U/ml penicillin, and 100 lg/ml streptomycin). Stable
LNCaP cell-lines, transfected with empty vector (LNCaP-EV),
wild-type Scap (LNCaP-Scap-WT), or Y234A-mutant Scap (LNCaP-
Scap-mut), were generated previously [34] and maintained in
Medium B (Medium A, supplemented with 250 lg/ml zeocin). Be-
fore plating LNCaP sub-lines, plates and dishes were treated with
polyethyleneimine (Sigma–Aldrich) to enhance cellular adhesion
as described previously [34].
The Chinese hamster ovary (CHO) cell-lines, CHO-7 and
sterol-regulation deﬁcient sub-line 1 (SRD-1), were a gift from
Dr. Michael Brown and Dr. Joseph Goldstein (University of Texas
Southwestern Medical Center, USA). SRD-15 cells were a gift from
Dr. Russell DeBose-Boyd (University of Texas Southwestern Medi-
cal Center, USA). CHO-7 cells were maintained in Medium C (DF12,
supplemented with 5% (v/v) NCLPDS, 100 U/ml penicillin, and100 lg/ml streptomycin). SRD-1 and SRD-15 cells were maintained
in Medium C, supplemented with 1 lg/ml 25-HC.
2.3. Cholesterol modulation and cholesterol assay
When modulating cholesterol levels, treatment conditions
(time and concentration) were optimised to produce the maximum
effect without compromising cell viability (data not shown). Fol-
lowing treatment, cells were harvested and cellular cholesterol lev-
els were determined as described previously [29].
2.4. Lactate assay
Following treatment, cells were incubated with or without
100 ng/ml oligomycin for 4 h. Oligomycin inhibits ATP synthase
and thus respiration, maximising glucose ﬂux into lactate
production.
The media was centrifuged at 2000g to remove detached cells
and the supernatant was assayed for lactate content in a microtitre
plate format: 10 ll of supernatant was diluted in 90 ll water in
duplicate wells. To one set of wells, 100 ll of assay buffer (4 mM
NAD+, 1 M glycine pH 9.2, 0.4 M hydrazine in 1.2 M NaOH,
2.5 mM EDTA), ﬁnal pH adjusted to 9.2 with NaOH) was added to
each well. The second set of wells received 100 ll of assay buffer,
supplemented with 2 U/ml lactate dehydrogenase (LDH). The ﬁrst
set of wells determines background NAD+ reduction, whilst the lat-
ter determines lactate-speciﬁc NAD+ reduction. After incubation
for 2 h at room temperature, the absorbance of NADH at 340 nm
was measured using the Spectra Max 340 plate-reader (Molecular
Devices, USA). Comparison with a lactate standard determined
media-lactate content.
Cells were harvested for protein with RIPA buffer (1% (v/v) NP-
40, 0.1% (w/v) sodium dodecylsulfate, 1 mM Na3VO4, 150 mM
NaCl, 20 mM Tris–HCl (pH 7.4), 5 mM EDTA, 0.5% (w/v) sodium-
deoxycholate). Protein content was determined using the Pierce
BCA assay kit (ThermoScientiﬁc, Vic, AU), using bovine serum albu-
min standard. Media lactate levels were normalised to protein
content.
2.5. Oxygen consumption analysis
Cellular oxygen consumption was measured using the
Oxygraph-2k (Oroboros Instruments, AT). Before each run, the
instrument was calibrated with Medium A, according to the man-
ufacturer’s instructions. Following treatment, cells were 60–70%
conﬂuent, although higher conﬂuences had little impact upon
oxygen consumption (Fig. S1A). Cells were trypsinised and
resuspended in Medium A (1  106 cells/ml), from which 2 ml
were added to each chamber.
After allowing the oxygen consumption rate to stabilise (Rate
A), cells were treated sequentially with 500 ng/ml oligomycin
(Rate B), 100 lM 2,4-dinitrophenol (Rate C), 0.25 lM rotenone,
and 12.5 lM antimycin A (Rate D). Oxygen consumption after each
treatment was calculated using DatLab (Oroboros), and the follow-
ing parameters calculated: basal respiration rate = A–D, leak respi-
ration rate = B–D, maximal respiration rate = C–D [35]. The
biological signiﬁcance of these parameters is explained in Section 3
and Fig. 2B.
2.6. Mitochondrial isolation
LNCaP cells (10  106 cells) were seeded in a 100 mm dish in
Medium A. Following treatment, mitochondria were harvested
using the anti-TOM22 mitochondrial isolation kit (Miltenyi Biotec,
NSW, AU), according to the manufacturer’s instructions.
Fig. 1. Cholesterol modulation does not inﬂuence lactate production. (A and B)
CHO-7 cells were treated with cholesterol/methyl-b-cyclodextrin (C/CD, 20 lg/ml)
for 4 h, or with 2-hydroxypropyl)-b-cyclodextrin (CD, 0.5% w/v) for 2 h, all in
Medium C. Cells were then assayed for (A) cholesterol content or (B) lactate
production in Medium C, with or without oligomycin (oligo, 100 ng/ml). (C and D)
LNCaP cells were treated with C/CD (20 lg/ml) or methyl-b-cyclodextrin (CD, 0.25%
w/v) for 2 h in Medium A. Cells were then assayed for (C) cholesterol content or (D)
lactate production in Medium A, with or without oligomycin (oligo, 100 ng/ml). All
data presented as mean + S.E., relative to the vehicle (Veh) condition, from at least
three separate experiments, each performed with triplicate wells per condition.
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Following culturing, RNA was harvested and reverse-transcribed,
and mRNA levels determined by quantitative real-time PCR
(qRT-PCR) as described previously [29]. All primers used have been
described previously [29].
2.8. Mitochondrial copy number analysis
Following culturing, cells were harvested for DNA as described
previously [36], except that a non-shaking waterbath was used
for overnight digestion. Furthermore, following extraction with
phenol:chloroform:isoamyl alcohol, an additional extraction with
1 vol of 24:1 (v/v) chloroform:isoamyl alcohol was performed prior
to precipitating DNA.
For mitochondrial copy number analysis, 25 ng DNA was used
as a template for qRT-PCR (described above). The mitochondrial
gene ampliﬁed was nicotinamide adenine dinucleotide dehydroge-
nase 1 (MT-ND1), with the following primers [37]: MT-ND1-F:Fig. 2. Cholesterol modulation does not inﬂuence respiration. (A) LNCaP cells were treate
(CD, 0.25% w/v) as described in Fig. 1. Following treatment, mitochondria (MT) were
triplicate determinations. Veh, vehicle. (B) Schematic showing the parameters of MT bioen
Max, maximal; Non-MT, non-mitochondrial (C) LNCaP cells were treated with C/CD an
mean + S.E., from four separate experiments.50-ACGCCATAAAACTCTTCACCAAAG-30 and MT-ND1-R: 50-
GGGTTCATAGTAGAAGAGCGATGG-30. The genomic reference gene
ampliﬁed was glyceraldehyde 3-phosphate dehydrogenase (GAP-
DH), with the following primers [38]: gGAPDH-F: 50-AACGTGTCAG
TGGTGGACCTG-30 and gGAPDH-R: 50-AGTGGGTGTCGCTGTTGAAGT-30.
These genes have been used previously in a PCa setting [37,38].
Relative mitochondrial copy number was calculated from MT-ND-
1 levels using the DDCt method, normalised to GAPDH.
3. Results
First, we tested the effect of cellular cholesterol levels on aero-
bic metabolism. We conducted pilot experiments using CHO cells,
since they have been used previously in this context [8], and are
commonly-used to study cholesterol homeostasis (e.g., [33,34]).
To modulate cholesterol levels, we used cholesterol–cyclodextrin
for cholesterol-loading and cyclodextrin alone for cholesterol-
depletion (Fig. 1A). However, neither treatment had any effect on
either basal or stimulated lactate production (Fig. 1B) – a change
in lactate production would have implied an opposite change in
respiration. Repeating these conditions in PCa (LNCaP) cells yielded
a similar result (Fig. 1C and D). Interestingly, oligomycin had a
greater effect on lactate production in LNCaP cells, with a 150%
increase (Fig. 1D) versus 50% increase in CHO-7 cells (Fig. 1B).
This implies CHO-7 cells heavily favour lactate production, reduc-
ing our potential effect size. Combined with our focus on the pros-
tate setting, we restricted subsequent experiments to LNCaP cells.
To assess whether these cyclodextrin treatments were inﬂuenc-
ing the mitochondria, we isolated mitochondria from treated
LNCaP cells. We found that mitochondrial-cholesterol content in-
creased markedly with cholesterol-loading (Fig. 2A). To examine
any downstream effects on respiration, we measured cellular oxy-
gen consumption, focusing on several parameters: (1) basal respira-
tion, (2) leak respiration, whereby ATP synthase is inhibited by
oligomycin yet oxygen is still consumed due to proton leak, and
(3) maximal respiration, whereby the proton gradient is dissipated
by the uncoupler 2,4-dinitrophenol (Fig. 2B). Furthermore, Com-
plexes I and III were inhibited by rotenone and antimycin A respec-
tively to obtain the non-mitochondrial respiration rate, which
provided the background value to calculate the basal, leak, and
maximal respiration rates (Fig. 2B, [35]). We found that cholesterol
modulation had no effect on oxygen consumption (Fig. 2C). Overall,
this shows that cellular cholesterol levels have little effect on aer-
obic metabolism in PCa cells.
Next, we tested the impact of SREBP-2 on aerobic metabolism.
Although previous studies have used CHO mutants with impaired
SREBP-2 activity for this purpose [8], our experiments with other
CHO mutants did not support a relationship between SREBP-2
activity and aerobic metabolism (Fig. S2). To test this relationshipd with cholesterol/methyl-b-cyclodextrin (C/CD, 20 lg/ml) or methyl-b-cyclodextrin
isolated and assayed for cholesterol content. Data presented as mean + S.D., from
ergetics. Details in the text. DNP, 2,4-dinitrophenol; Rot, rotenone; AA, antimycin A;
d CD as described in (A), and assayed for oxygen consumption. Data presented as
Fig. 3. Overexpression of Scap promotes respiration. (A–D) LNCaP-EV (‘EV’), LNCaP-Scap-WT (‘WT’), and LNCaP-Scap-mut (‘mut’) cells were grown in Medium B. (A) Cells
were harvested for RNA and assayed for mRNA expression, relative to the EV cells. (B) Cells were then assayed for lactate production in Medium A, with or without oligomycin
(oligo, 100 ng/ml). This was made relative to the EV/vehicle (Veh) condition. (C) Cells were assayed for oxygen consumption. Max, maximal. (D) Cells were harvested for DNA
and assayed for mitochondrial copy number, made relative to one batch of EV cells. (A–D) Data presented as mean + S.E., from at least three separate experiments, with (A–B)
performed with triplicate wells per condition.
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cells which stably express the SREBP-2 regulator, Scap. We com-
pared these cells to LNCaP cells stably transfected with the empty
vector (LNCaP-EV) or a mutant form of Scap (LNCaP-Scap-mut).
Conﬁrming previous ﬁndings [34], LNCaP-Scap-WT and LNCaP-
Scap-mut have higher Scap expression than LNCaP-EV cells
(Fig. 3A, left panel). Although LNCaP-Scap-mut has higher Scap
expression than LNCaP-Scap-WT, this Scap is mutated so it cannot
activate SREBP-2. Consequently, only LNCaP-Scap-WT had higher
expression of SREBP-2 target genes, HMGCR and LDLR (Fig. 3A,mid-
dle and right panels), demonstrating it has higher SREBP-2 activity
than LNCaP-EV or LNCaP-Scap-mut cells.
Consequently, we expected LNCaP-Scap cells to have lower res-
piration. Surprisingly, we observed the reverse, with LNCaP-Scap
cells having 48% lower lactate production (Fig. 3B, vehicle condi-
tion) and 36% higher basal respiration (Fig. 3C) than LNCaP-EV or
LNCaP-Scap-mut cells. Cell number was similar when preparing
the cells for these assays (Fig. S1B), implying that this is not due
to a difference in growth-rates. These stable cell-lines responded
similarly to the metabolic inhibitors, having similar lactate produc-
tion with oligomyin treatment (Fig. 3B), leak respiration rates
(Fig. 3C), minimal respiration rates and maximum respira-
tion:basal respiration ratios (data not shown, P > 0.05, paired t-test
between each pair of cell-lines). In addition, these cell-lines had a
similar mitochondrial copy number (Fig. 3D). Thus, these differ-
ences in aerobic metabolism are not due to mitochondrial dysfunc-
tion, but likely because of Scap overexpression itself.
4. Discussion
In this study, we explored the interplay between cholesterol
and aerobic metabolism, using both CHO and prostate cells.
Although modulating cholesterol levels had little effect (Figs. 1
and 2), we found that overexpression of Scap promoted respiration
and reduced lactate production (Fig. 3).
Although we observed no clear effects with CHO cells (Figs. 1,
S2), a previous study by Khan et al. [8] used CHO cells to show that
cholesterol modulation with cyclodextrin and mutant sublineswith perturbed SREBP-2 activity inﬂuence respiration: increased
cellular cholesterol levels reduced respiration due to impaired oxy-
gen diffusion across the cholesterol-enriched plasma membrane.
We did not observe these ﬁndings here for several possible rea-
sons. Firstly, we assessed aerobic metabolism by lactate production
instead of respiration, because the lactate assay is higher-through-
put and there were differences in mitochondrial number between
the CHO-7 mutants (Fig. S2D). Secondly, we used CHO-7 cells
whilst other CHO cells were used previously [8] – CHO-7 are
adapted to low-sterol conditions (NCLPDS) compared to other
CHO cells (grown in FCS [8]), and thus would respond differently
to cholesterol modulations. Furthermore, we found the CHO-7 cells
heavily favour lactate production (Fig. 1B), which would reduce
any apparent effect size for cholesterol enrichment or enhanced
SREBP-2 activity. Thirdly, Khan et al. achieved up to 300% choles-
terol enrichment [8], but exceeding our 160% enrichment
(Fig. 1A) compromises CHO-7 cell viability (data not shown). Thus,
our conﬂicting ﬁndings can be reconciled.
We similarly found that cholesterol modulation had no effect on
lactate production or respiration in LNCaP cells (Figs. 1D and 2C),
even though mitochondrial cholesterol levels were affected
(Fig. 2D). By contrast, in the hepatoma setting, increased mitochon-
drial cholesterol levels impair respiratory activity (e.g., [18]). In
addition, one group found that cholesterol enrichment promotes
the export of citrate out of the mitochondria, truncating the citric
acid cycle [39,40]. However, it was later demonstrated that choles-
terol-loading liver mitochondria physiologically (via diet) did not
truncate the citric acid cycle or affect respiration [41]. Thus, supra-
physiological cholesterol enrichment may be required to inﬂuence
respiration in a hepatic setting. However, the prostate synthesises
more cholesterol than the liver [4] and thus may be more suscep-
tible to cholesterol enrichment. Hence, future investigations
should compare mitochondria between prostate epithelial cells
and the surrounding tissue. This would determine if there is a high-
er mitochondrial cholesterol content in prostate epithelial cells,
whether this impairs respiration and contributes to the citrate
accumulation in the prostate [5,21,22], and if these parameters
change during progression to PCa.
Fig. 4. A key regulator of lipid homeostasis, Scap, promotes respiration and inhibits
lactate production. Details provided in the main text.
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sion promoted respiration and reduced lactate production
(Fig. 3). In contrast, this effect was not seen when the overexpres-
sed Scap was mutated speciﬁcally to prevent it from facilitating
SREBP-2 transport (LNCaP-Scap-mut, Fig. 3). To explore this fur-
ther, we attempted to generate LNCaP cells stably-expressing ma-
ture SREBP-2, but were not successful (data not shown).
Furthermore, Scap not only activates SREBP-2, but the other SREBP
isoforms, SREBP-1a and 1c, which are also involved in fatty acid
metabolism. Consequently, we found that overexpressing wild-
type Scap increased the expression of fatty acid synthase (FASN)
by 2.3 ± 0.2-fold (n = 3), whereas mutant Scap had no effect on
FASN expression (0.9 ± 0.1-fold, n = 3). We hypothesised that like
SREBP-2, this would have diverted acetyl-CoA to lipid synthesis,
thus impairing respiration, but our Scap-overexpression experi-
ments would suggest otherwise (Fig. 3). A recent study found that
SREBP-2 target gene expression is higher in normal prostate epi-
thelial cells than PCa cells in vitro [42], whilst we found no change
as PCa cells progress to advanced (castration-resistant) PCa [43]. In
line with our results here, this would suggest that the highly glyco-
lytic nature of prostate epithelial cells is enhanced during carcino-
genesis. It would be interesting to examine if this is the case in a
more physiological setting, such as with tissue slices as used in
past studies (e.g., [4]).
Whilst the relationship between SREBP-2 activity and aerobic
metabolism has not been deeply explored, studies have shown that
overexpression of SREBP-1 isoforms in ﬁbroblasts or hepatoma
cells inﬂuences the expression of mitochondrial proteins (e.g.,
[44,45]), also seen by ChIP with endogenous SREBP-1 (e.g., [46]).
Furthermore, overexpressing either mature SREBP-1a or -1c in-
creased the expression of GLUT4, involved in glucose uptake, and
enhanced glucose oxidation and glycogen synthesis [44]. Although
it is unclear whether this is due to an overall increase in glucose
metabolism or speciﬁc changes to glucose ﬂux, the SREBP isoforms
could be similarly overexpressed in prostate cells to dissect iso-
form-speciﬁc effects on glucose metabolism.
Another important catabolite is glutamine, which transformed
cells utilise as an alternate carbon source [47] – our ﬁndings could
be explained by increased glucose ﬂux through the pentose phos-
phate pathway and glutamine ﬂux through aerobic respiration.
Although a previous study showed that SREBP-1c overexpression
did not affect glutamate dehydrogenase expression [48], assays
comparing glutamine metabolism should be considered in future
SREBP-overexpression studies. Flux-rate analysis of the glycoly-
sis–citric acid cycle network and microarray analysis for genome-
wide, SREBP-dependent changes in gene expression could identify
the relevant SREBP targets mediating any potential differences in
glucose and glutamine metabolism. This has implications beyond
prostate metabolism, given that Scap has been considered a targetfor modulating SREBPs in metabolic disease [49,50] and recent
interest in targeting carbon metabolism in cancer therapy [2,3],
including PCa [31].
Overall, we have shown that the overexpression of a key regu-
lator of lipid homeostasis, Scap, promotes respiration in prostate
cells (Fig. 4). Although modulating cell cholesterol levels had little
effect on respiration, it is possible that Scap inﬂuences glucose ﬂux.
Given that the SREBP isoforms are regulated by growth-promoting
factors [26,28,29,34], particularly by androgens in a prostate set-
ting [28,29], future investigations should explore this work in or-
der to better understand the metabolic phenotype of the prostate.
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